• About us
• Contact

Advertisement

Organisation › Details

AGC Biologics GmbH (Heidelberg)

Biomeva GmbH is a reliable and experienced contract manufacturing organization (CMO) in the biopharmaceutical industry and dedicated to meeting the manufacturing needs for the production of microbially and plant cell culture expressed protein products. Since 1993, BIOMEVA has been producing more than 400 batches of GMP-compliant material for pharmaceutical and biotech companies. Partners benefit from BIOMEVA's track-proven operational expertise in the transfer, development, scale-up and validation of GMP processes. Biomeva's state-of-the-art GMP production facility and extensive technical expertise are recognized worldwide and provide the necessary support for regulatory approval. Biomeva is privately owned and located in Heidelberg, Germany. *

 

	Start	2006-01-01 renamed
	Group	Asahi Glass (AGC) (Group)
	Predecessor	Biomeva GmbH
	Industry	contract manufacturing (biologicals)
	Industry 2	recombinant protein production in bacterial cells
	Region	Heidelberg
	Country	Germany
	Street	22 Czernyring
	City	69115 Heidelberg
	Tel	+49-6221-9026-0
		Address record changed: 2022-09-17
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-12-30

Advertisement

More documents for Asahi Glass (AGC) (Group)

• [1] AGC Biologics. (9/13/21). "Press Release: AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility". Heidelberg....
• [2] AGC Biologics. (8/20/21). "Press Release: AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site". Copenhagen....
• [3] MolMed S.p.A.. (4/14/20). "Press Release: MolMed: the Board of Directors, Based on the Scientific Evidence from the Experiments on Early-stage Pre-clinical Products, Decided to Suspend the Investments in These Projects". Milan....
• [4] MolMed S.p.A. (at the request of AGC Inc.). (4/2/20). "Press Release: Offer Document Filed with Consob. Voluntary Public Tender Offer Launched by AGC Inc. on All the Ordinary Shares of MolMed S.p.A. [Not for release where violation of laws or regulations...
• [5] AGC Inc.. (3/17/20). "Press Release: AGC Decides to Launch Voluntary Tender Offer for Shares of MolMed"....
• [6] MolMed S.p.A.. (3/9/20). "Press Release: The Board of Directors Approved the 2019 Full Year Financial Results". Milan....
• [7] MolMed S.p.A.. (3/6/20). "Press Release: MolMed Signs a Multi-year Agreement and Announces the Beginning of a New Collaboration in the Field of T Cell Therapies". Milan....
• [8] MolMed S.p.A.. (12/18/19). "Press Release: Italy – the EIB Supports MolMed Investment in Research, Development and Manufacturing for Cancer and Rare Diseases Innovative Treatments". Oxford....
• [9] MolMed S.p.A.. (10/10/19). "Press Release: MolMed Informs on Its Decision to Withdraw the Conditional Marketing Authorization of Zalmoxis". Milan....
• [10] MolMed S.p.A.. (3/13/19). "Press Release: Partnership in the Field of Rare Genetic Diseases with Rocket Pharma Extended to Three New Therapeutic Indications". Milan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.